title: Does chloroquine therapy of porphyria cutanea tarda influence liver pathology?
abstract: BACKGROUND
  Porphyria cutanea tarda (PCT) is regularly associated with changes in liver tissue. On the other hand, systematic investigations are lacking on whether there is a correlation between the severity of liver damage and chloroquine treatment.
  
  
  METHODS
  During a 20-year period, liver biopsies were obtained in 89 patients with PCT confirmed by biochemical analysis of urine and feces and low-dose chloroquine therapy. Seventeen patients with alcohol-induced liver disease were excluded. In 8 of 63 patients, only a single biopsy was available. Classification of liver damage was performed according to the Riedel score. Electron microscopy was available from 24 patients. In a second group of patients, the HFE status was investigated and Berlin blue stains of liver biopsies were performed.
  
  
  RESULTS
  There was no correlation between the duration of cutaneous symptoms and liver pathology. After 12 months chloroquine treatment, 45 patients (81%) disclosed an improvement of liver pathology, nine (16%) had no change, and a worsening was observed in one patient (3%). All patients achieved a complete clinical and biochemical remission. In 13 of 16 patients with a relapse, there was again a deterioration of liver damage. Patients with HFE mutations had a significant higher risk (P < 0.05) for hepatic siderosis.
  
  
  CONCLUSIONS
  The severity of liver damage was not correlated with the disease duration. Chloroquine treatment resulted in PCT remission (clinical and biochemical) and in 81% to an improvement of liver morphology.
authors.affiliation: Department of Dermatology and Allergology, Hospital Dresden-Friedrichstadt, Academic Teaching Hospital of the Technical University of Dresden, Germany. wollina-uw@khdf.de
authors.forename: U
authors.initials: U
authors.lastname: Wollina
authors.forename: E
authors.initials: E
authors.lastname: Köstler
authors.forename: A
authors.initials: A
authors.lastname: Koch
authors.forename: H
authors.initials: H
authors.lastname: Riedel
authors.forename: U
authors.initials: U
authors.lastname: Stölzel
mesh_terms: D000962:Antimalarials / Q000008:administration & dosage*; D001706:Biopsy; D002738:Chloroquine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D000071020:Hemochromatosis Protein; D006486:Hemosiderosis / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D008565:Membrane Proteins / Q000235:genetics; D017119:Porphyria Cutanea Tarda / Q000150:complications / Q000188:drug therapy*; D012720:Severity of Illness Index
chemical_list: D000962:Antimalarials; C103673:HFE protein, human; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D002738:Chloroquine